Published in Cancer Weekly, October 26th, 2004
"Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two associated with poor outcomes," oncologists in the United States explained.
"Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors," noted T.O. Nielsen and colleagues at the University of North Carolina, who "sought to develop a clinical assay for breast basal-like tumors."
"To identify an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.